IH01 - Full-Lifecycle Acceleration of Clinical Trials with a GAI Multi-Agent Systems

IH01 - Full-Lifecycle Acceleration of Clinical Trials with a GAI Multi-Agent Systems

Tuesday, March 24, 2026 10:05 AM to 10:30 AM · 25 min. (Europe/Amsterdam)
Exhibition Hall/Innovation Hub (3rd floor)
Sponsored Session
Track 2 - Clinical Trials Innovation

Information

Deep Intelligent Pharma (DIP) offers an AI-native platform powered by “Digital Rehearsal,” which simulates clinical trials end-to-end before first-patient-in to identify risks early, strengthen quality, and accelerate timelines. Moving beyond fragmented, paper-heavy execution, DIP enables sponsors to virtually test and optimize each stage—from protocol design through data management, analysis, and final reporting—so trials run more predictably and patients gain faster access to breakthrough therapies.

DIPG4Founded in 2017, Deep Intelligent Pharma (DIP) is a technology company dedicated to human-machine collaborative pharmaceutical R&D services. Powered by the synergy of Generative AI (GenAI) and expert teams, DIP offers a unique service model that moves beyond traditional platform sales or software licensing fees. Instead, we work on a project basis to customize, build, and operate dedicated end-to-end GenAI multi-agent systems for clinical trials. This approach allows us to deliver result-oriented, full-stack services backed by a fully auditable quality system. With operation centers strategically located in Singapore, the US, China, and Japan, DIP has successfully served over 1,000 global clients. We are committed to the highest standards of quality management, information security, and privacy compliance, holding multiple international certifications including ISO 9001, ISO 17100, ISO/IEC 20000-1, ISO/IEC 27001, ISO/IEC 27017/27018, and ISO/IEC 27701.

Documents & Links

26101_IH01_Full-Lifecycle Acceleration of Clinical Trials with a GAI Multi-Agent